Search

Author/Creator Jensen, Morten K

2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10253 (12th September 2020)

Authors:
Olivotto, Iacopo; Oreziak, Artur; Barriales-Villa, Roberto; Abraham, Theodore P; Masri, Ahmad; Garcia-Pavia, Pablo; Saberi, Sara; Lakdawala, Neal K; Wheeler, Matthew T; Owens, Anjali; Kubanek, Milos; Wojakowski, Wojciech; Jensen, Morten K; Gimeno-Blanes, Juan; Afshar, Kia; Myers, Jonathan; Hegde,...
Journal:
Lancet
Issue:
Volume 396:Issue 10253(2020)
Page Start:
759
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Issue Volume 20:Issue FI 2(2018) (18th September 2017)

Authors:
Liebregts, Max; Faber, Lothar; Jensen, Morten K; Vriesendorp, Pieter A; Hansen, Peter R; Seggewiss, Hubert; Horstkotte, Dieter; Adlova, Radka; Michels, Michelle; Bundgaard, Henning; ten Berg, Jurriën M; Veselka, Josef
Journal:
Europace
Issue:
Volume 20:Issue FI 2(2018)
Page Start:
f198
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search